Onconova Therapeutics Inc.

230 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium

  6/10/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.

• Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital

  6/3/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.

• Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

  6/1/2021

   Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chief Medical Officer

• Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

  5/21/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel multi-kinase inhibitor.

• Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

  5/20/2021

  Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021.

• Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/17/2021

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced financial results for the three months ended March 31, 2021 and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17.

  5/10/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2021 financial results on Monday, May 17, 2021.

• Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma

  4/22/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).

• Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in ChinaCorporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group

  4/1/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China.

• Onconova to Present at the Spring 2021 Oncology Investor Conference

  3/29/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will present a Company overview and hold one-on-one meetings during the Spring 2021 Oncology Investor Conference, sponsored by the National Foundation for Cancer Research.

• Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update

  3/11/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer, announces financial results for the twelve months ended December 31, 2020 and provides a business update.

• Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results

  3/4/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will release its year-end 2020 financial results on Thursday, March 11, 2021

• Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March

  3/1/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March

• Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

  2/24/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces receipt of notification from Nasdaq that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2

• Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option

  2/16/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced underwritten public offering. A total of 28,750,000 shares of its common stock were sold, including 3,750,000 shares of common stock

• Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference

  2/16/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual Company update at the 2021 BIO CEO & Investor Digital Conference being held February 16-18, 2021.

• Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock - Feb 11, 2021

  2/11/2021

  Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share.

• Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

  2/10/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering

• Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event

  1/14/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, President & CEO, will present a Company overview at NobleCon17, Noble Capital Markets Seventeenth Annual Small and Microcap Investor Conference being held virtually January 19th and 20th.

• Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering

  1/7/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain institutional accredited investors to purchase in a registered direct offering 19,550,562 shares of its common stock at a purchase price of $0.445 per share.